Guggenheim Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price target reduced by stock analysts at Guggenheim from $3.00 to $1.75 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. ADAP has been the subject of several other research reports. StockNews.com assumed coverage on shares […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price target reduced by stock analysts at Guggenheim from $3.00 to $1.75 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. ADAP has been the subject of several other research reports. StockNews.com assumed coverage on shares […]
